Home » BMS Buys Cormorant for $520M
BMS Buys Cormorant for $520M
July 8, 2016
Bristol-Myers Squibb has purchased Cormorant Pharmaceuticals for $520 million, both companies disclosed Wednesday.
Under the deal, BMS will gain all outstanding shares and the rights to Cormorant’s HuMax-IL8, which Cormorant previously gained from Genmab in 2012.
The agreement includes an up-front payment of around $95 million, with the remaining $425 million tied to development and regulatory milestones.
Upcoming Events
-
21Oct